Skip to content
10-Q

Quarterly Report

Aptose Biosciences Inc. APTOF

0001193125-26-221955

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 2.55M sh
Shares Diluted Q1 2026 · Mar 31, 2026 2.55M sh
Shares Diluted Q1 2026 · Mar 31, 2025 2.13M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$5.84M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.8M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$34.67M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$27.17M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$7.39M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$4.54M
Current Liabilities Q1 2026 · Mar 31, 2026 $11.24M
Current Liabilities Q1 2026 · Dec 31, 2025 $9.31M
Total Liabilities Q1 2026 · Mar 31, 2026 $45.4M
Total Liabilities Q1 2026 · Dec 31, 2025 $37.18M
Current Assets Q1 2026 · Mar 31, 2026 $6.16M
Current Assets Q1 2026 · Dec 31, 2025 $6.45M
Total Assets Q1 2026 · Mar 31, 2026 $10.72M
Total Assets Q1 2026 · Dec 31, 2025 $10.01M
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.99
Eps Diluted Q1 2026 · Mar 31, 2025 −$2.61
Eps Basic Q1 2026 · Mar 31, 2026 −$2.99
Eps Basic Q1 2026 · Mar 31, 2025 −$2.61
Sga Expense Q1 2026 · Mar 31, 2026 $3.56M
Sga Expense Q1 2026 · Mar 31, 2025 $3.1M
Rd Expense Q1 2026 · Mar 31, 2026 $3.62M
Rd Expense Q1 2026 · Mar 31, 2025 $2.36M
Net Income Q1 2026 · Mar 31, 2026 −$7.63M
Net Income Q1 2026 · Mar 31, 2025 −$5.54M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $0